Press Releases
Looking for more press releases? Explore our full press release archive by date to access past announcements, news updates, and media releases published on Fintech World Post.
Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity
GlobeNewswire, Inc.
·
August 14, 2025
BOSTON and ATLANTA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely,...
Hesai Group Reports Second Quarter 2025 Unaudited Financial Results
GlobeNewswire, Inc.
·
August 14, 2025
Quarterly net revenues were RMB706.4 million (US$98.6 million)1 Quarterly lidar shipments were 352,095 units Quarterly net income was RMB44.1 million (US$6.2 million) SHANGHAI, China, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Hesai Group (“Hesai” or the...
Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights
GlobeNewswire, Inc.
·
August 14, 2025
PEMGARDA® (pemivibart) net product revenue of $11.8 million reported for Q2 2025, representing 413% growth year-over-year Invivyd’s target of near-term profitability (1H 2025) was not met but remains possible with the upcoming respiratory virus...
Cibus Reports Second Quarter Financial Results and Provides Year-to-Date Business Update for 2025
GlobeNewswire, Inc.
·
August 14, 2025
Streamlining operational focus on Rice herbicide tolerance traits and partner-funded and/or supported programs, expected to reduce annual cash usage to approximately $30 million by 2026 Commercialization of Rice herbicide tolerance traits HT1 and...
Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights
GlobeNewswire, Inc.
·
August 14, 2025
Announced CNSide® CSF assay platform launch timeline Initiated the REYOBIQ dose optimization trial for patients with leptomeningeal metastases HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the...
Arcadia Biosciences (RKDA) Announces Second Quarter and First Half 2025 Financial Results and Business Highlights
GlobeNewswire, Inc.
·
August 14, 2025
-- Arcadia revenues increase 11% year over year driven by 24% growth in Zola® -- -- Arcadia receives 2.7 million shares of stock in ABVE -- -- Arcadia eliminates $1M in liabilities -- DALLAS, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Arcadia Biosciences,...
Yellow Tail Tech Earns Third Straight Inc. 5000 Honor, Highlighting Growth and Impact in Tech Education
EIN Presswire
·
August 14, 2025
Yellow Tail Tech has earned its third consecutive spot on the Inc. 5000 list, recognizing its sustained growth, resilience, and impact. SILVER SPRING, MD, UNITED STATES, August 14, 2025 /EINPresswire.com/ -- Yellow Tail Tech, a trailblazing...
Reviva Reports Second Quarter 2025 Financial Results and Recent Business Highlights
GlobeNewswire, Inc.
·
August 14, 2025
– Well-tolerated safety profile and robust broad-spectrum efficacy sustained over 1-year across all symptom domains including negative symptoms in open label extension (OLE) 1-year trial– – Successful completion of two large randomized...
Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
GlobeNewswire, Inc.
·
August 14, 2025
Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received ~$28 million at closing and is eligible to receive up to an additional $4.8 million under a contingent value right (CVR), plus a 2.5% royalty on future net sales...
Banzai Reports Second Quarter 2025 Financial Results
GlobeNewswire, Inc.
·
August 14, 2025
Revenue of $3.3 Million for Q2 2025, Representing 205% Growth from Q2 2024 Gross Profit of $2.7 Million for Q2 2025, Representing 267% Growth from Q2 2024; Gross Margin Expanded to 83.0% in Q2 2025 a 1390 BPS Increase Management to Host Second...
Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results
GlobeNewswire, Inc.
·
August 14, 2025
Updated data from ongoing open-label Phase 1b trial demonstrated a mean 12-month eGFR of approximately 68 mL/min/1.73 m2 post-transplant for patients on tegoprubart Company on track to report topline results from Phase 2 BESTOW trial in kidney...
Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire, Inc.
·
August 14, 2025
Next-generation claudin 18.2 ISAC BDC-4182 now in Phase 1 dose-escalation study Cash balance of $48.5 million as of June 30, 2025 anticipated to fund key milestones through mid-2026 REDWOOD CITY, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Bolt...
Birchtech Reports Second Quarter 2025 Financial Results
GlobeNewswire, Inc.
·
August 14, 2025
Second Quarter 2025 Revenues Totaled $3.3 Million, Driven by Continued Industry Recognition of Intellectual Property Portfolio CORSICANA, Texas, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Birchtech Corp. (TSX: BCHT) (OTCQB: BCHT) ("Birchtech" or the...
Pyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire, Inc.
·
August 14, 2025
– Phase 1 monotherapy expansion study of micvotabart pelidotin (MICVO) for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients progressing well with preliminary data in second half of 2025 and first half of 2026 –...
CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights
GlobeNewswire, Inc.
·
August 14, 2025
Presented positive translational data from SYNGAP1-related disorders program showcasing efficacy in a humanized SYNGAP mouse model and increased protein in non-human primates at the 28th American Society of Gene and Cell Therapy (ASGCT) Annual...
ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2025
GlobeNewswire, Inc.
·
August 14, 2025
PORTLAND, Maine, Aug. 14, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve...
Profound Medical Announces Second Quarter 2025 Financial Results
GlobeNewswire, Inc.
·
August 14, 2025
TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the...
Intchains Group Limited Reports Second Quarter and First Half 2025 Financial Results
GlobeNewswire, Inc.
·
August 14, 2025
Reinforces its Leading ETH Treasury Position: Increased ETH holdings to 8,816 as of June 30, 2025, up 26% from March 31, 2025, and 55% from December 31, 2024 Updates on Its Long-Term Dollar-Cost Averaging ETH Treasury Strategy Designed to Boost...
MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities
GlobeNewswire, Inc.
·
August 14, 2025
Newly-appointed President and CEO, Eric Risser, outlines strategic priorities for 2025 and 2026 Received $70 million upfront cash payment from Sagard Healthcare Partners under a royalty purchase agreement for ZYNYZ® Cash, cash equivalents and...
Century Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire, Inc.
·
August 14, 2025
Patient dosing ongoing in CALiPSO-1 trial; on track to report clinical data for CNTY-101 in patients with B-cell-mediated autoimmune diseases by year-end 2025 CNTY-308, a CAR-iT cell therapy functionally comparable to primary T cells, now in...